Probiotics-Study – Examination of the effect of the regular ingestion of the probiotic Lactobacillus reuteri on the health of male adults in a workplace setting

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00004430

Enrollment

234

Registered

2012-11-07

Start date

2012-11-29

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J00 K52.9

Interventions

Group 1: One chewable tablet ("BioGaia ProTectis") with the probiotic Lactobacillus reuteri (at least 100000000 CFU) per day over a period of 90 days. Group 2: Placebo tablet in the same period of 90

Eligibility

Sex/Gender

Male

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: No retirement during the study period

Exclusion criteria

Exclusion criteria: Age (younger than 18 or older than 65), sex (female), retirement during the study period, pre-existing conditions (diabetes, cancer, abscesses, pancreatitis, HIV, organ transplantation)

Design outcomes

Primary

Measure	Time frame
Primary outcome is the number of days of absence reported by the participants in the diary.	—

Secondary

Measure	Time frame
Participants report in a diary format any symptoms of infections of the respiratory and the digestive system. By this means it is possible to examine frequency and duration of the symptoms as secondary outcomes.	—

Countries

Germany

Contacts

Public ContactKlaus Giersiepen

Universität Bremen

giersiepen@zes.uni-bremen.de0421 218 58551

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026